Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (2407)	4/17/1999 7:11:00 PM
From: Bob Swift	Read Replies (2) \| Respond to of 10280

Steven, Sorry if it sounds like I was talking about their patent. I was merely amazed at the similarity of the precise language the FDA letter demands when compare to the patent reviewer response I encounter before. That said, there is no doubt that Xopenex is a better drug. The rewriting of the press release will hopefully clarify the situation and explain why it is better - i.e. that the same dose 0.63 mg of the R isomer works better alone than when mixed with the S isomer. I was also wrong about the directors' register selling which occurs before 3/26/99 at a time(3/17 and 3/22) when SEPR was at around 140. Looks like a case of market timing instead. I will still vote against them for creating the panic which snowballed out of proportion.